We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Using NT-proBNP to Detect Chronic Heart Failure in Patients With Chronic Obstructive Pulmonary Disease (NT-proBNP)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01801722
First Posted: March 1, 2013
Last Update Posted: March 1, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Elzbieta Kaszuba, Lund University
  Purpose
The aim of the present study was to evaluate if the analysis of NT-proBNP might be used as an initial step for the diagnosis of chronic heart failure in patients with COPD in primary health care, and to select patients for a further examination by echocardiography.

Condition
Chronic Obstructive Pulmonary Disease Chronic Heart Failure

Study Type: Observational
Study Design: Time Perspective: Cross-Sectional
Official Title: Using NT-proBNP to Detect Chronic Heart Failure in Patients With Chronic Obstructive Pulmonary Disease.

Resource links provided by NLM:


Further study details as provided by Elzbieta Kaszuba, Lund University:

Primary Outcome Measures:
  • Percentage of patients with elevated NT-proBNP. [ Time Frame: 3 months ]
    NT-proBNP has taken only once in each patient without follow up follow up. Three months was a period when we collected data from all participants.


Secondary Outcome Measures:
  • Percentage of patients with abnormal left ventricular function assessed by echocardiography. Association between elevated NT-proBNP and symptoms, signs and electrocardiography. [ Time Frame: 3 months ]
    Echocardiography was performed once in each referred patient. Three months was a period of data collection.


Enrollment: 75
Study Start Date: April 2008
Study Completion Date: June 2008
Primary Completion Date: June 2008 (Final data collection date for primary outcome measure)
Groups/Cohorts
NT-proBNP,ejection fraction ,COPD stage.
The group comprised 25 women (47%) and 28 men (53%). The mean age was 75.4 years (SD 7.9), 76.3 (SD 7.6) for men and 74.4 (SD 8.2) for women.

Detailed Description:

Patients with a confirmed diagnosis of COPD were examined regarding chronic heart failure.

  1. An interview regarding symptoms: breathlessness, orthopnoea, night cough, nocturia, walking distance.
  2. Physical examination: weight and height, heart and lung auscultation, blood pressure measurement after 5 minutes' rest in the sitting position and the presence of peripheral oedema.
  3. Electrocardiography.
  4. Natriuretic peptide- NT-proBNP (Immulite 2500, Siemens Healthcare Diagnostics AB Sweden).
  5. Patients with the NT-proBNP level of > 1200 pg/ml were referred for echocardiography to assess left ventricular function.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   65 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients aged 65 years and older with a registered diagnosis of COPD.
Criteria

Inclusion Criteria:

  • Patients aged 65 years and older with the following diagnosis codes according to International Statistical Classification of Diseases and Related Health Problems - Tenth Revision:J44 (COPD) and J41, J42 (chronic bronchitis) registered during the period 1 January 2008-16 April 2008 according to the electronic patient record.

Exclusion Criteria:

  • Impaired cognitive function and/or anticipated difficulties in carrying out spirometry due to immobility,
  • psychiatric disorders or terminal illness.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01801722


Locations
Sweden
Primary health care center.
Olofström, Blekinge, Sweden, 29332
Sponsors and Collaborators
Lund University
Investigators
Principal Investigator: Elzbieta Kaszuba, PhD student Lund University
  More Information

Responsible Party: Elzbieta Kaszuba, PhD student, Lund University
ClinicalTrials.gov Identifier: NCT01801722     History of Changes
Other Study ID Numbers: 502008
DN50/2008 ( Other Identifier: Ethics committee at Lund university )
First Submitted: February 25, 2013
First Posted: March 1, 2013
Last Update Posted: March 1, 2013
Last Verified: February 2013

Additional relevant MeSH terms:
Heart Failure
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Heart Diseases
Cardiovascular Diseases
Respiratory Tract Diseases


To Top